Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business 
Venezuela Earthquake Health Risks Rise as Disease Monitoring Intensifies 
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election 
White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak 
UNAIDS Urges U.S. to Reconsider South Africa HIV Funding Withdrawal 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
US Tightens Ebola Controls as Congo Outbreak Sparks Global Concern 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
Medicare to Cover GLP-1 Weight-Loss and Diabetes Drugs Starting July 1 
RFK Jr. Orders Extended Hantavirus Quarantine for Cruise Passenger 
Samsung to Launch First Yongin Chip Plant by 2029 as South Korea Speeds Up Semiconductor Hub 
NIH Infectious Disease Leadership Shake-Up Raises Concerns Amid Ebola, Hantavirus Outbreaks 
RFK Jr. Spokesman Resigns Over Trump Administration’s Flavored E-Cigarette Policy 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
The government is ‘doubling down’ on its social media ban. But bigger penalties for platforms aren’t enough 
German healthcare and materials company Merck KGaA (NSE:PROR) announced on Monday that it has agreed to acquire U.S.-based biotech firm SpringWorks Therapeutics in a deal valued at approximately $3.9 billion. The acquisition is aimed at strengthening Merck’s oncology business and expanding its pipeline of cancer therapies.
The Darmstadt-headquartered group said it will pay $47 per share in cash for SpringWorks, representing a premium over the company’s recent trading price. The deal assigns SpringWorks an equity value of $3.9 billion and an enterprise value of around $3.4 billion (3.0 billion euros) after adjusting for the biotech firm's cash reserves.
SpringWorks Therapeutics specializes in developing targeted therapies for severe rare diseases and cancers, with its lead product, nirogacestat, positioned to treat desmoid tumors. The acquisition will give Merck access to a promising late-stage oncology asset and enhance its long-term growth prospects in the competitive cancer treatment market.
This move aligns with Merck's strategic focus on innovation and expanding its specialty medicine portfolio. The transaction is expected to strengthen its presence in the U.S. biotech sector and accelerate the development of novel oncology solutions for patients worldwide.
The acquisition is subject to customary closing conditions, including regulatory approvals, and is expected to finalize later this year.
